Nature Reviews Clinical Oncology - Table of Contents alert Volume 11 Issue 2

If you are unable to see the message below, click here to view.

Advertisement
Wondering where to publish your next paper?  Frontiers is at the forefront of building the ultimate Open Science platform. We are the first - and only - platform that combines open-access publishing with research networking, with the goal to increase the reach of publications and ultimately the impact of articles and their authors. Submit your paper today and become a part of the future of research publication.
TABLE OF CONTENTS
February 2014 Volume 11 Number 2
Impact Factor 15.031 *	In this issue Editorial Research Highlights Year in Review Reviews Also this month  Featured article: Rapid learning for precision oncology Jeff Shrager & Jay M. Tenenbaum
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
Nature Outlook Cancer Immunotherapy New treatments enhance natural defences to fight malignancy  Access the Outlook free online for six months. Produced with support of a medical education grant from Bristol-Myers Squibb and with support of a grant from Dendreon Corp., F. Hoffmann-La Roche Ltd and Merck & Co., Inc.
EDITORIAL		Top
Predicting cancer's next move Lisa Hutchinson Published online: 30 January 2014 p61 | doi:10.1038/nrclinonc.2014.4 Full Text | PDF
RESEARCH HIGHLIGHTS Top Skin cancer: Setting the stage for cutaneous SCC Published online: 21 January 2014 p63 | doi:10.1038/nrclinonc.2014.2 PDF Targeted therapies: Juggling combinations—not the way forward Published online: 17 December 2013 p64 | doi:10.1038/nrclinonc.2013.238 PDF Haematological malignancies: Double act in follicular lymphoma Published online: 21 January 2014 p64 | doi:10.1038/nrclinonc.2014.1 PDF Haematological cancer: Ikaros—not a myth for myeloma Published online: 17 December 2013 p65 | doi:10.1038/nrclinonc.2013.237 PDF Radiotherapy: A double-edged sword for NSCLC? Published online: 24 December 2013 p66 | doi:10.1038/nrclinonc.2013.247 PDF Targeted therapies: New rational design approach to optimize combination therapy strategies Published online: 24 December 2013 p66 | doi:10.1038/nrclinonc.2013.248 PDF Basic research: Antifungal treatment for glioma? Published online: 24 December 2013 p67 | doi:10.1038/nrclinonc.2013.249 PDF Haematological cancer: Deep molecular response predicts survival in CML Published online: 17 December 2013 p68 | doi:10.1038/nrclinonc.2013.235 PDF Haematological cancer: Radioimmunotherapy—time to be upfront and fractionated? Published online: 17 December 2013 p68 | doi:10.1038/nrclinonc.2013.236 PDF IN BRIEF From ASH—chronic lymphocytic leukaemia: More-effective treatment for patients with comorbidities | From ASH—multiple myeloma: Options for patients ineligible for stem-cell transplantation | From ASH—acute myeloid leukaemia: Improving event-free survival in paediatric patients PDF Clinical Oncology JOBS of the week Endowed Research Chair, Pediatric Hematology / Oncology Penn State Hershey Children?s Hospital A cancer biology postdoctoral position at University of Wisconsin-Madison University of Wisconsin - Madison Medical Oncologist - solid tumor physician scientist University of Chicago Post-Doctoral Research Fellow University of Nevada Las Vegas postdoctoral fellow MD Anderson Cancer Center More Science jobs from Clinical Oncology EVENT 7th Oncology Biomarkers 19.03.14 San Diego, USA More science events from
YEAR IN REVIEW		Top
Lung cancer in 2013: Refining standard practice and admitting uncertainty Stephen V. Liu & Giuseppe Giaccone Published online: 21 January 2014 p69 | doi:10.1038/nrclinonc.2013.251 In 2013, the treatment of several NSCLC subtypes was refined. PROFILE-1007 and LUX-Lung 3 confirmed that targeted therapy was superior to chemotherapy, whereas NCIC BR19 and PointBreak failed to show superiority of adjuvant gefitinib and combined maintenance therapy, respectively. These studies reinforced some practices and discouraged others, underscoring the need for new prospective studies. Full Text | PDF
Breast cancer in 2013: Genomics, drug approval, and optimal treatment duration Adrian V. Lee & Nancy E. Davidson Published online: 14 January 2014 p71 | doi:10.1038/nrclinonc.2013.250 2013 saw much progress in breast cancer research. Advances in high-throughput technologies continue to refine our knowledge of the molecular biology of breast cancer, and are beginning to give insight into cancer evolution, drug resistance, and how to deploy precision therapeutics. Full Text | PDF
Liver cancer in 2013: Mutational landscape of HCC—the end of the beginning Augusto Villanueva & Josep M. Llovet Published online: 07 January 2014 p73 | doi:10.1038/nrclinonc.2013.243 Next-generation sequencing analysis and characterization of the microenvironment 'field-effect' that promotes hepatocellular carcinoma (HCC) development has revealed critical players and potential targets for chemoprevention. A biomarker-based drug development strategy is needed to improve future HCC clinical trials and therapies. Full Text | PDF
Melanoma in 2013: Melanoma—the run of success continues Dirk Schadendorf & Axel Hauschild Published online: 14 January 2014 p75 | doi:10.1038/nrclinonc.2013.246 In 2013, new insights on the molecular features of cutaneous melanoma provided a paradigm shift in our understanding of the biology of this disease. Exploiting immune checkpoint blockade and the use of BRAF-targeted or MAPK-targeted agents contributed to important progress in the treatment and management of cutaneous melanoma. Full Text | PDF
Cervical cancer in 2013: Screening comes of age and treatment progress continues Chris J. L. M. Meijer & Peter J. F. Snijders Published online: 21 January 2014 p77 | doi:10.1038/nrclinonc.2013.252 In 2013, studies confirmed that HPV infection of target cells predisposes to cervical (pre)cancer. In developed countries, HPV screening revealed superior protection than cytology screening. In India, visual inspection of the cervix after acetic acid application significantly reduced cervical cancer mortality after 12 years. Improved survival for women with advanced disease was observed after adjuvant bevacizumab. Full Text | PDF
Colorectal cancer in 2013: Towards improved drugs, combinations and patient selection Hans-Joachim Schmoll & Alexander Stein Published online: 21 January 2014 p79 | doi:10.1038/nrclinonc.2013.254 The year 2013 has brought more options for patients with metastatic colorectal cancer (mCRC) with new ways to combine traditional agents, further refinement of predictive molecular for EGFR inhibitors and a new salvage option. Molecular profiling could identify subgroups to further improve treatment selection. Full Text | PDF
REVIEWS		Top
Biomarker enrichment strategies: matching trial design to biomarker credentials Boris Freidlin & Edward L. Korn Published online: 26 November 2013 p81 | doi:10.1038/nrclinonc.2013.218 Many targeted anticancer treatments may benefit only a subgroup of the histologically-defined population and thus may be missed by traditional randomized clinical trial designs that focus on the overall treatment effect. New biomarker driven designs can help to identify subgroups of patients who are most likely to benefit from these treatments. In this Review the authors discuss how to select appropriate designs and analysis strategies for phase III, biomarker driven clinical trials, using specific examples to illustrate their advantages (and disadvantages). Abstract | Full Text | PDF
Mitigating the toxic effects of anticancer immunotherapy Tara C. Gangadhar & Robert H. Vonderheide Published online: 21 January 2014 p91 | doi:10.1038/nrclinonc.2013.245 Novel approaches for cancer therapy take advantage of the modulation of the immune system. Immunotherapy is however associated with a number of adverse effects and clinicians will need to become familiar with recognizing and managing them. In this Review the authors describes the toxicity profiles for various anticancer therapies based on immunomodulatory agents. Abstract | Full Text | PDF
End-of-life care—what do cancer patients want? Shaheen A. Khan, Barbara Gomes & Irene J. Higginson Published online: 26 November 2013 p100 | doi:10.1038/nrclinonc.2013.217 Is there such a thing as a 'good death'? Palliative care services alleviate the debilitating physical symptoms and psychological distress that patients with cancer frequently experience at the end of their lives. In this Review, Khan and colleagues discuss the preferences of these patients and how advance care planning can help in meeting these choices. Abstract | Full Text | PDF
Rapid learning for precision oncology Jeff Shrager & Jay M. Tenenbaum Published online: 21 January 2014 p109 | doi:10.1038/nrclinonc.2013.244 In this Review, Jeff Shrager and Marty Tenenbaum describe the latest generation of Precision Oncology, and the different ways to keep refining it. In Precision Oncology 3.0, each treatment event provides the chance to learn from it so that such treatment can be applied to other patients with similar characteristics without facing the difficult economic and structural challenges of a clinical trial. Abstract | Full Text | PDF
Advertisement
NATURE REVIEWS CANCER & NATURE REVIEWS CLINICAL ONCOLOGY 2014 CALENDAR  Download the calendar for FREE As well as plundering the Nature Reviews Cancer image bank for more clinically oriented figures for our 2014 calendar, we have chosen six images and figures from our sister journal, Nature Reviews Clinical Oncology. Our calendar is freely available thanks to support from  OriGene
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*Journal Citation Reports, Thomson, 2012. Nature Reviews Clinical Oncology was previously published as Nature Clinical Practice Oncology.

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2014 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.